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Oral Contraceptive Steroids as Promoters
or Complete Carcinogens for Liver in
Female Sprague Dawley Rats
by James D. Yager, Jr.*
Published reports have described an increased incidence of adenomas and of hepatocellular carci-
nomas in livers of women with a history of long-term oral contraceptive use. Evidence derived from
human and experimental animals suggests that oral contraceptive steroids may be liver tumor pro-
moters.
Experiments were designed to determine the initiating and/or promoting potential of two oral
contraceptive steroids, namely mestranol and norethynodrel. The results show that: mestranol and
norethynodrel can promote DEN-initiated hepatocarcinogenesis, as indicated by increased numbers
of y-glutamyl transpeptidase-positive, putative preneoplastic lesions and by the appearance of
carcinomas. Various synthetic estrogens fail to cause detectable levels of DNA damage in
hepatocytes. Mestranol has weak, if any, initiating potential. Neither mestranol nor norethynodrel
exhibits antiglucocorticoid activity. Mestranol and norethynodrel inhibit metabolic cooperation in
V-79 Chinese hamster cells. Taken together, these results and those reported by others demonstrate
that oral contraceptive steroids are relatively strong promoters of hepatocarcinogenesis and have
little if any genotoxic effect.
Introduction
Previous reports have indicated that women who
are long-term users of oral contraceptive steroids
(OCS) are at increased risk of developing liver
adenomas and hepatocellular carcinomas (1, 2). The
data on the carcinogenicity of OCS in animals and
humans, together with reports that such synthetic
estrogens are not mutagenic in bacterial or
mammalian cells suggest that they might be
promoters of hepatocarcinogenesis (1-4).
Recent studies reported by Taper (5), Cameron et
al. (6) and our laboratory (1) employing experimental
animal model systems have demonstrated that vari-
ous OCS, particularly estrogens, can promote chemi-
cal carcinogen-initiated hepatocarcinogenesis. Taper
(5), using ovariectomized female Wistar rats, demon-
strated that chronic treatment with estradiol-17-
phenylproprionate and estradiol benzoate, following
initiation with N-nitrosomorpholine, enhanced the
appearance of liver foci, nodules and hepatocellular
carcinomas. More recently, Cameron et al. (6) re-
ported that feeding ethinyl estradiol to diethylni-
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trosamine initiated male Fischer 344 rats enhanced
the appearance of y-glutamyl transpeptidase-
positive foci (putative preneoplastic lesions) and hy-
perplastic nodules.
This paper presents a brief review of our previ-
ously published work on the promoting (1, 2) and
genotoxic (2, 7) properties of oral contraceptive
steroids. In addition, data on the effects of these
agents on the glucocorticoid response of cultured
hepatoma cells and on the metabolic cooperation in
V-79 Chinese hamster cells (8) is reported.
Materials and Methods
Female Sprague-Dawley rats (Charles River
Breeding Laboratories, Inc., Wilmington, MA) were
housed individually in wire bottom cages under con-
trolled conditions of temperature, humidity and
lighting. All animal diets were semipurified and
obtained from Teklad (Madison, WI). Mestranol (M),
norethynodrel (N) and phenobarbital (PB) were
mixed into the diet and fed as previously reported
U).
For the promotion studies, at 7 weeks of age the
animals were subjected to a partial hepatectomy fol-
lowed, 24 hr later, by treatment with diethylnitro-J. D. YAGER, JR.
samine (DEN) at 5 mg/kg body weight, or H20. At
24 hr thereafter, the animals were transferred to
various treatment groups: (1) DEN -* M; (2) DEN -
N;(3)DEN - M + N;(4)H2O -M + N;(5)DEN
PB; (6) H20 - PB; and (7) DEN -- basal diet. The
OCS were fed at a dose level equivalent to 10 to 15
times the human level (1) which was for M, 0.02-
0.03 mg/kg and for N, 0.5-0.75 mg/kg body
weight/day. Phenobarbital was present at 0.05% in
the diet which provides 19.4 to 27.4 mg/kg body
weight/day. The animals were fed the various diets
for 4 and 9 months (only the 9 month data are pre-
sented here). At the time of killing, the livers were
processed for determination of the number of y-glu-
tamyl transpeptidase (GGT)positive foci and histo-
pathologic evaluation as previously reported (1).
Studies on the effects of mestranol and norethy-
nodrel on metabolic cooperation were carried out by
Dr. J. E. Trosko as described by Yotti et al. (9).
Analysis of the initiating and genotoxic potential of
various OCS were carried out in vivo and in
primary cultures of rat hepatocytes and described
by Yager and Fifield (7). Studies on the effects of M
and N on the induction of tyrosine amino trans-
ferase (TAT) were done by using H-35 hepatoma
cells provided by Ms. Joyce Becker (McArdle Labo-
ratory for Cancer Research, U. Wisconsin, Madison,
WI). The H-35 hepatoma cells were cultured in S-77
medium + 5% fetal calf serum, 20% horse serum
and 4 mM glutamine. After 2 days of culture to near
confluency in 6 cm dishes, the medium was changed
to serum-free and the experiments were conducted
24 hr later. Test compounds were dissolved in eth-
anol, and TAT activity was determined as described
by Butcher et al. (10) using the method of
Diamondstone (11). One unit of activity is equal to 1
,umole of p-hydroxyphenylpyruvic acid formed/mg
soluble protein/hour. Protein was determined by the
method of Hartree (12).
Results and Discussion
In a previous paper (1), we reported that two oral
contraceptive steroids, particularly mestranol, en-
hanced the appearance of GGT-positive putative
preneoplastic lesions in the livers of DEN-initiated
female Sprague-Dawley rats after both 4 and 9
months of treatment. Body weights were signifi-
cantly lower in all groups ingesting M and/or N
throughout the course of the experiment. At 9
months, liver weights per 100 g body weight were
significantly greater in the groups receiving PB, M,
N and M + N (1). The data in Table 1 were adapted
from our previous report (1) and show the number
of GGT-positive foci/cm2 in the livers of animals
from the various treatment groups. These data
clearly show that M, M + N and the positive
control, PB, significantly enhanced the number of
GGT-positive foci. Norethynodrel alone caused a
significant increase in GGT foci at 4 months (not
shown) but not at 9 months. When one considers
that M was present in the diet at approximately
0.125% the level of PB, it seems that M is a strong
promoter, at least on a dose-for-dose basis.
It can also be seen from Table 1 that the number
of GGT-positive foci was slightly but significantly el-
evated in the non-DEN-treated group fed M + N
(H2O -- M + N). Recent results (Yager, unpublished
observations) have demonstrated that feeding mes-
tranol alone also results in a small but significant
dose-dependent increase in GGT-positive foci. This
is in contrast to PB, which does not cause an in-
crease in such foci (Table 1). These results, together
with other reports in the literature (13, 14) suggest
that M, in addition to being a strong promoter,
might have weak initiating potential and thus be
capable of acting as a weak complete carcinogen (7).
Recently, we reported the results of studies
aimed at determining whether mestranol has any
initiating potential, and whether various OCS are
genotoxic to hepatocytes (7). The results of these
studies were negative. Using an initiation/promo-
tion protocol, M had little, if any, ability to act as an
initiator of the development of GGT-positive foci. In
addition, neither M, N, nor ethinyl estradiol caused
detectable levels of hepatocyte DNA damage dem-
onstrating thus that they are not genotoxic agents
(7). These results support the work of others who
have failed to detect any ability by various synthe-
tic estrogens to cause mutagenesis in the Ames as-
say (3), in mammalian cells (4) or chromosomal
damage in rat bone marrow cells (15). Altogether,
these results support the notion that the OCS are
not genotoxic agents, whose effects are mediated
via damage to DNA. Rather, these compounds may
be strong promoters, acting on a spontaneous level
Table 1. GGT focVcm2 and percent rats of with
GGT foci at 9 months.a
Rats with
Group GGT Foci/cm2b foci, %
DEN- M 8.6 +2.4*t 100
DEN-N 4.1+ 2.7 60
DEN-M + N 7.3 ± 1.8t** 100
H20-M+ N 2.4 ± 0.8t 100
DEN-PB 6.4 ± 1.6t 100
H20-PB 0.2+ 0.1 30
DEN-Basal 0.3± 0.1 60
a Adapted from Yager and Yager (1).
b Mean ± SE for ten animals/group.
* Significantly different from H20-M + N group, p<0.01.
t Significantly different from DEN-basal group,p<0.001.
** Significantly different from H20-aM + N group,p<0.005.
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of initiation in the non-DEN-initiated animals or on
the latent initiated cells in DEN-treated animals.
Additional experiments were conducted to explore
some of the types of effects these agents exert on
mammalian cells.
Phenobarbital, various OCS, progesterone and
many other compounds are growth stimulatory for
liver (16, 17). Loeb (18) has shown that cortico-
steroids inhibit DNA synthesis in liver cells. Desser-
Wiest has reported that progesterone stimulates
DNA synthesis and mitosis in liver and in cultured
hepatoma cells, and that progesterone can prevent
the liver cell growth inhibitory effects of cor-
ticosterone (17, 19). Thus, Desser-Wiest (17) has
proposed a model by which progesterone can
stimulate liver growth through inactivation of the
corticosteroid receptors. Since some OCS are
progesterone analogs, and since estradiol has been
reported to be able to inhibit the energy-dependent
uptake of corticosterone in isolated hepatocytes (20),
we decided to determine whether M, N or M + N
can inhibit the effects of hydrocortisone.
Glucocorticoid hormones induce TAT in liver
cells and cells derived from hepatomas, including H-
35 cells (10). The data in Figure 1 show that TAT
activity increases approximately twofold 6 hr fol-
lowing treatment with 10-6 M hydrocortisone (HC).
The induction of TAT by hydrocortisone was
inhibited in a dose dependent manner by the simul-
taneous presence of progesterone, supporting the
Desser-Wiest model (17) that progesterone inter-
feres with glucocorticoid effects. In contrast, N did
not inhibit the induction of TAT by HC, except at
10-4 M, where toxicity to the cells was evident. On
the other hand, M did appear to have some inhibi-
tory effect at 10-5M, but not at the lower concentra-
tions where progesterone was still significantly ef-
fective. These results suggest that the effect on
liver growth by these two OCS is probably not me-
diated through inhibition of the growth inhibitory
effects of corticosteroids by receptor inactivation as
postulated for progesterone (17).
Of the many effects of tumor promoters on cells,
their ability to inhibit metabolic cooperation, a
measure of cell-cell communication, has recently
received considerable attention (2, 9, 21-25). If
growth regulatory information is exchanged be-
tween cells through gap junctions which mediate
cell-cell communication, perhaps the inhibition of
this process would create an environment where
initiated cells, subtly altered in their sensitivity to
growth regulatory factors, can begin to grow (25,
26). Together with Dr. Trosko, preliminary studies
have been carried out to determine the effect of M,
N and ethinyl estradiol on metabolic cooperation in
V-79 Chinese hamster cells (8, 9). The results in
5
4
' 3
'1-4
1-
=1
uninduced
control
* Progesterone
o Mestranol (M)
Norethynodrel (N)
& M + N
O -7 -6
LOG CONCENTRATION
-5 -4
FIGURE 1. Effect of progesterone, mestranol and norethyn-
odrel on the induction of TAT by hydrocortisone. H-35
hepatoma cells were cultured in S-77 medium supple-
mented with 5% fetal calf serum, 20% horse serum and 4
mM glutamine. At 24 hr prior to hormone addition, the
cells were transferred to serum free medium. Hydrocorti-
sone was added at 10- 6M, and the other hormones were
added 30 min prior to hydrocortisone addition. The cells
were harvested for TAT determination 6 hr later. One unit
of TAT activity equals 1 pmole ofp-hydroxyphenylpyruvic
acid formed/mg soluble protein/hr.
Table 2. Effects of various OCS on metabolic cooperation.a
Recovery of
Treatment Dose, M 6T6r-V79 cells, %
- - 48
TPAb lo-7 117
Mestranol 2.5 x 10-6 61
Ethinyl estradiol 2.5 x 10-6 66
Norethynodrel 2.5 x 10-6 85
a The assay was carried out as described by Yotti et al. (9).
b 12-O-tetradecanoylphorbol-13-acetate.
Table 2 indicate that these three OCS significantly
inhibit metabolic cooperation in this cell culture
system (8). While more detailed dose-response
studies are required, these results suggest that the
role of inhibition of cell-cell communication in
promotion of hepatocarcinogenesis by the OCS
needs to be investigated.
ill112 J. D. YAGER, JR.
Conclusions
The results of our own work, together with those
of others, indicate that various oral contraceptive
steroids, particularly the synthetic estrogens, are
promoters of hepatocarcinogenesis. The lack of de-
tectable genotoxic and mutagenic effects suggests
that they are not complete carcinogens, but rather
compounds that modify and enhance the carcinogen-
ic process through as yet unknown mechanisms.
While these compounds could be classified as acting
through epigenetic mechanisms as defined by Weis-
burger and Williams (20), we would prefer not to
use that term and simply say that their mode of
action appears to involve mechanisms other than
genotoxic and mutagenic effects. Much additional
study is required to determine the mechanism(s) of
action of these agents in particular, and promoters
in general.
This work was supported by grant CA 23916 from the Na-
tional Cancer Institute, DHEW.
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